Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme® and Renagel® are registered trademarks and RenvelaTM is a trademark of Genzyme Corporation. All rights reserved.

This press release contains forward-looking statements including, without limitation, statements about the development of Renvela™ for chronic kidney disease and alternative dosing regimens for the powder formulation of Renvela™. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: additional analysis of the data comparing the powder form of Renvela™ to Renagel®; the results of other studies and whether such results are consistent with this data; the actual efficacy and safety of Renvela™ for chronic kidney disease; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of Renvela™ for chronic kidney disease and the timing of such discussions; the timing and content of submissions to and decisions made by regulatory authorities; the availability and extent of third
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/28/2014)... 2014  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" ... the development, marketing and distribution of opioid-related immunotherapies, ... materials with the Securities and Exchange Commission in ... to be held on Thursday, September 4, 2014, ... date for determining those shareholders eligible to receive ...
(Date:7/28/2014)... 2014 ResMed (NYSE: RMD ), ... cura dei disturbi respiratori del sonno (SDB) e altre ... in Germania contro il produttore Taiwanese di dispositivi medicali, ... apparecchiature da indossare in testa, che violano i brevetti, ... La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... , July 28, 2014  ResMed (NYSE: ... products for the treatment of sleep-disordered breathing and other ... Germany against Taiwanese medical device ... headgear used on APEX WiZARD 210 and 220 masks.  ... in Munich , is appealable, and ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... Dec. 30, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services ... CCM ), operator of the largest ... China, comments on the newly issued Foreign Investment ... healthcare service sectors to "permitted" from "restricted" category. ...
... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ) ... Food and Drug Administration (FDA) that a Risk Evaluation ... been approved.  The program, which will be referred to ... Program, was designed to ensure informed risk-benefit decisions before ...
Cached Medicine Technology:Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 2Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- Elementary school students seem to ... them, according to a new study of school officials. ... of Agriculture -- went into effect in the fall of ... stop buying lunch, or throw away most of their food. ... that this isn,t the case. , , "The updated meals ...
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... ) filed on behalf of individuals who were ... Hip Replacement System continue to move forward in U.S. ... reports. According to an Order issued on July 18, ... of a motion filed by the Plaintiffs’ Steering Committee ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... chronic medical conditions people have at retirement age, the ... claims. Since nearly four in five older ... Bloomberg School of Public Health in Baltimore said the ... are slowing in the United States. "Living with ... heart failure is now the norm and not the ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 (HealthDay ... are more likely to get a pacemaker than people without ... of more than 16,000 people found that those with dementia ... pacemaker than those without the memory-robbing condition. What ... are so much more likely to be treated with a ...
Breaking Medicine News(10 mins):Health News:Healthy School Lunches Get Thumbs Up From Students 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
... PHILADELPHIA - Despite recent concerns that medications for attention ... cardiovascular events in children and adolescents, an observational study ... of Medicine and HealthCore Inc. finds they are no ... than those who do not take the drugs. The ...
... treated with hormone therapy to suppress tumor growth, obese ... worsening, researchers at Duke University Medical Center have found. ... annual meeting Sunday (May 15, 2011), advances the link ... interest in recent years as the incidence of both ...
... simple, minimally-invasive technique using cells from the interior of the ... and most treatable stages, according to a study ... presented at the ATS 2011 International Conference. "Our data ... in the interior surface of the nose may serve as ...
... May 13 (HealthDay News) -- A program to boost heart health ... that it,s being expanded to about 20 middle schools in the ... getting the students to: Eat more fruits and ... Get at least 150 minutes of physical activity a week , ...
... , FRIDAY, May 13 (HealthDay News) -- Teenagers ... their computers for activities not related to their schoolwork, a ... in New York City found that visiting social networking sites ... linked to drinking. The study, published in the May ...
... , THURSDAY, May 12 (HealthDay News) -- People with ... partners by more than 90 percent if they start ... still relatively healthy, researchers announced Thursday. The study, ... was supposed to last until 2015, but the results ...
Cached Medicine News:Health News:No increase in severe cardiovascular events for children, adolescents taking ADHD medications 2Health News:Obesity linked to higher risk of prostate cancer progression 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Teaching Kids to Make Healthier Choices May Pay Off 2Health News:Teens Who Drink Seem Drawn to Social Networking Sites 2Health News:Early HIV Drug Therapy Protects Sex Partners From Virus 2Health News:Early HIV Drug Therapy Protects Sex Partners From Virus 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: